Ico Therapeutics (QB) Stock Price

0.00 (0.0%)
Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
Ultimate Trader (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Ico Therapeutics Inc (QB) ICOTF OTCMarkets Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.0372 15:59:34
Open Price Low Price High Price Close Price Previous Close
0.0372 0.0372
Bid Price Ask Price Spread News
0.0288 0.04 0.0112 - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.0372 USD

Ico Therapeutics (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 5.72M 153.75M 153.04M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
615.00 $ - 0.00% - -

more financials information »

Ico Therapeutics (QB) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ICOTF Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.02890.03720.02890.02915633,4330.008328.72%
1 Month0.03660.03720.02890.02954798,7130.00061.64%
3 Months0.03190.0440.02870.034754340,2280.005316.61%
6 Months0.02770.0480.02390.033294131,3070.009534.3%
1 Year0.04610.06530.01550.035055644,688-0.0089-19.31%
3 Years0.02950.20350.01550.062553438,7390.007726.1%
5 Years0.03190.20350.01110.053406537,3460.005316.61%

Ico Therapeutics (QB) Description

iCo Therapeutics in-licenses and redefines existing drug candidates or generics by employing reformulation and delivery technologies for new or expanded use indications. The Company holds worldwide rights to an oral drug delivery platform, with Oral Amphotericin B (Amp B) as the initial platform candidate, utilizing a known anti-fungal drug to treat life-threatening infectious diseases. Oral Amp B has completed a Phase 1 clinical trial. iCo also has worldwide rights to iCo-008, a monoclonal antibody targeting eotaxin-1. With Phase 2 clinical history, Bertilimumab (iCo-008) is candidate for the treatment of vernal or atopic keratoconjunctivitis and Bullous Pemphigoid.

Your Recent History
Ico Therap..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.